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In 2008, two human papillomavirus (HPV) vaccines, Cervarix® and Gardasil®, were licensed for use in South Africa. Initial models 
showed that vaccination could lead to an approximate 70% decline in cervical cancer cases. This paper describes the knowledge, 
awareness and health beliefs about HPV and the HPV vaccine, and the intentions of female tertiary students with respect of 
being vaccinated with the latter. An observational, descriptive and analytical cross-sectional survey was conducted among 150 
female tertiary students at a university in the Eastern Cape province in this regard. Knowledge and awareness of HPV and the 
HPV vaccine were poor. Only 22.7% of the students were aware of HPV and that an HPV vaccine was available in South Africa. 
However, most respondents (80%) reported a willingness to be vaccinated. Being aware of the existence of a Papanicolaou 
smear, higher knowledge of HPV, higher perceived vaccine effectiveness and higher perceived severity of HPV infection were 
significantly associated with increased willingness to be vaccinated. There is a need for education on HPV and its vaccination 
in South Africa. An effective vaccine marketing strategy should emphasise the effectiveness of the vaccine, the susceptibility of 
women to contracting HPV and the severity of being infected with the human immunodeficiency virus. 
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Introduction
Women in South Africa have a high prevalence of human 
papillomavirus (HPV) infection. The highest rates of infection 
are found in sexually active adults who are younger than 25 
years of age.1 HPV type 16 (high risk) is the most dominant 
type that is found in South Africa.2 Cervical cancer is the 
second most common cancer in South African women. There 
is an overall age-standardised incidence rate of 30/100 000/
year.3 After it became evident that HPV played a role in the 
genesis of cervical cancer, vaccines against HPV infections 
were developed. Currently, a massive drive for vaccination is 
underway worldwide.4,5 In March 2008, two new prophylactic 
HPV vaccines, a bivalent vaccine that targets HPV 16 and 
18 (Cervarix®, GlaxoSmithKline), and a quadrivalent vaccine 
directed at HPV 16, 18, 6 and 11 (Gardasil®, Merck, and Sharpe 
and Dohme) were licensed for use in South Africa. However, 
they are not yet available in the public health sector.6 Modelling 
studies have shown that if fully implemented, vaccination 
can lead to a 31% reduction in precancerous lesions, which 
translates to an approximate 68% decline in cervical cancer 
cases.7 Therefore, a vaccination programme is an urgent priority 
in South Africa for the primary prevention of cervical cancer. 
This complements other strategies against cervical cancer that 
are already being implemented, such as the national cervical 
screening programme, aimed at the secondary prevention of 
cancer since not all women will be vaccinated.8
Research1,9 has found that between 10% and 39% of sexually 
active young adult women aged 18-25 years are infected 
with high-risk HPV at any point in time. Since the majority of 
university students are in that age group, they can be used 
as a proxy for this high-risk group. It is also noteworthy that 
female students will soon be mothers, if they are not already 
so, and are more likely to play a key role in HPV vaccination 
in the future if the universal vaccination of 11- to 12-year-
old girls is recommended in South Africa, as has been the 
case in other countries.10 This is largely because people often 
infer others’ needs from their own, and thus one may assume 
that women would deduce their daughter’s need for HPV 
vaccination based on their own perceived needs.11
The health belief model (HBM) suggests that key predictors 
for the acceptability of any vaccine include perceived disease 
likelihood and severity, perceived vaccine benefits and barriers, 
and cues to action.12-14 In the context of HPV vaccination, 
“perceived likelihood” is the belief that HPV infection and 
cervical cancer are likely outcomes. “Perceived severity” is 
the belief that HPV infection and cervical cancer would have 
serious negative health consequences. “Perceived vaccine 
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effectiveness”, i.e. perceived benefit, is the belief that the 
HPV vaccine will reduce the risk of HPV infection or cervical 
cancer. Perceived barriers can be any perceived impediment to 
vaccination, such as cost. Cues to action are situational factors 
that prompt one to get vaccinated. Interventions15,16 guided by 
the HBM have been shown to increase vaccination rates.
A significant body of literature exists on issues relating to 
HPV vaccine acceptability.17 However, these studies focus on 
awareness and knowledge of cervical cancer, HPV and the 
HPV vaccine in relation to potential uptake and resistance 
in developed countries. To date, little research has been 
conducted in developing countries, and in South Africa, 
in particular. It is equally important that the predictors of 
women’s interest in HPV education and their desire to have the 
HPV vaccination have not been characterised in this country 
where a significant number of females are able to benefit from 
the vaccination. Hence, it is necessary that local information 
guides the formulation of policies, and the introduction and 
propagation of the HPV vaccination in South Africa.
This paper describes the knowledge and awareness of HPV 
and the HPV vaccine in female university students, and factors 
that influenced their willingness to be vaccinated with the HPV 
vaccine. 
Method
This was an observational, descriptive and analytical cross-
sectional study, conducted in 2009, in a university in the 
Eastern Cape province to describe the knowledge, awareness 
and health beliefs about HPV and the HPV vaccine, and factors 
that influenced the intentions of female students with regard 
to vaccine uptake.
Study population and sampling
Participants were female students registered at the university 
in 2009 and attending lectures at the time of the study 
(n = 5 000). Based on a population of 5 000, using a very 
conservative estimate that 20% of them were aware of 
HPV and cervical cancer, and allowing 15% or 25% as the 
worst acceptable values using a 95% confidence interval, 
the required calculated sample size was determined as 150, 
using Epi Info™.
A stratified random sampling method was employed to obtain 
a representative sample of the female students. Each of the 
five faculties was considered to be a homogeneous stratum. A 
random sample of 30 participants was then selected from each 
faculty. Stratified sampling was chosen mainly as a means of 
saving time and money because the target population was 
spread out.
Ethical considerations
Ethical clearance for the study was granted by the University 
of the Western Cape Senate Research Committee. Permission 
to conduct the study was obtained from the registrar of the 
university where the research was conducted. Participation 
in the study was voluntary and based on informed consent. 
Anonymity and confidentiality were maintained at all times.
Data collection procedure 
Self-administered, anonymous, confidential questionnaires 
consisting of closed-ended questions were used to collect 
information. Interested participants in each faculty office were 
issued with an information sheet which they read and signed, 
before completing an attached questionnaire to demonstrate 
their informed consent. The information sheet explained the 
purpose of the survey and provided study participants with 
detailed information on their rights, as enshrined in the Human 
Sciences Research Council’s18 ethical guidelines. At the end 
of each day, the five offices were visited and the completed 
questionnaires collected, until 30 were filled in each faculty. 
It took two-and-a-half weeks to obtain the required number 
(150) of completed questionnaires.
The instrument
The questionnaire (survey instrument) used in this study was 
a modified version of the knowledge and perceptions (KAP) 
survey.19 Questions to ascertain knowledge of the existence of 
the HPV vaccine, perceived barriers and benefits, self-efficacy 
with regard to obtaining more HPV-related education and the 
desire to receive the HPV vaccination, were incorporated in the 
KAP survey for the purpose of this study. Each HBM variable 
was operationalised via a 4-point Likert scale. In addition, 
questions on participants’ number of sexual partners in the 
last 12 months, and their intentions with regard to obtaining 
more information on HPV and being vaccinated with the HPV 
vaccine to prevent HPV infection were added. Demographic 
characteristics included age, level of study at the university 
and ethnic background.
Data analysis
Epi Info™ 7 was used for data analysis in the study. Double 
entry was carried out and both data sets compared using the 
Epi Info™ data compare function. Any differences between 
the two data sets were checked and corrected appropriately 
using the original questionnaire. 
Means and standard deviations (SD) were calculated for 
continuous variables for the descriptive analysis, and 
frequencies computed for categorical variables. Bivariate 
analysis was performed to assess the relationship between 
predictor variables and intention with regard to vaccine 
uptake. 
Results
Demographic and behavioural characteristics
The mean age of the respondents was 22 years (SD 2.3 years). 
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Most respondents were South African (70.7%) and black 
(88%). Most (79%) were senior students, i.e. second-, third- 
and fourth-year students, taking undergraduate degrees) 
(Table I).
Table I: The demographic and behavioural characteristics of the 
participants (n = 150)
Characteristics Frequency Percentage
Age (years)
18-20 37 24.7
21-24 87 58
25-30 26 17.3
Race 
Black 132 88
Coloured 8 5.3
Asian or Indian 6 4
White 4 2.7
Nationality 
South African 106 70.7
Non-South African 44 29.3
Year of study
First 31 20.7
Second 66 4
Third 34 22.7
Fourth 12 8
Postgraduate 7 4.7
Behavioural characteristics
In a relationship 107 71.3
Sexually active 107 71.3
Had more than one sexual partner in the 
last six months
40 37.4
Used a condom during the last sexual 
encounter
65 60.7
Most respondents reported being in a relationship (71%) and 
sexually active (71%). More than a third of sexually active 
active respondents (37%) indicated that they had had more 
than one sexual partner in the past six months. More than half 
of the sexually active participants (60.7%) indicated that they 
used a condom during their last sexual encounter.
Knowledge and awareness of human papillomavirus 
and the human papillomavirus vaccine
Few study participants (23%) had heard of HPV, whereas 
most were familiar with cancer of the cervix (90%) and the 
Papanicolaou (Pap) smear (70%) (Table II). Media (electronic 
and print) was the most common source of information that 
reached 58% of respondents. Healthcare institutions ranked 
second (25%), followed by family and friends (25%).
Knowledge was generally limited. None of the participants 
were able to answer all 11 questions correctly. The mode score 
was 4 with a median of 4. Less than 5% (seven) answered 
75% of the questions correctly, and 22% answered none of 
them correctly. Most respondents (72%) were “not sure” of 
the association between HPV and herpes. Only 9.3% gave 
the correct answer. On the other hand, 67.3% of respondents 
knew that there was a link between HPV and cancer of the 
cervix. Also, 43% of respondents were aware of the link 
between HPV and genital warts. 
Less than a third (32%) of respondents knew that a vaccine 
existed to prevent HPV and cervical cancer, and only 22% (33) 
of the study participants were aware that the vaccine was 
available in the country. 
Health beliefs and intention with regard to human 
papillomavirus vaccine uptake
Table III indicates that risk perception by respondents of 
HPV was low. 41.3% believed that they were at risk. Most 
considered HPV infection and its consequences to be severe 
(78%), and thought that being vaccinated would effectively 
protect them against HPV (83.3%). Interestingly, most of 
the participants (98%) indicated a desire to receive more 
information on the HPV infection, cervical cancer and the HPV 
vaccine.
Slightly over 80% of the students were willing to be vaccinated 
if the vaccine was available. Vaccine uptake would be greatest 
in study respondents if it could prevent cancer (71.3%) and 
Table II: Knowledge and awareness of human papillomavirus and the 
human papillomavirus vaccine
Knowledge and awareness Frequency Percentage
Knowledge items
HPV can cause herpes 14 9.3
Genital warts are caused by HPV 65 43.3
HPV can cause cancer of the cervix 101 67.3
If the Pap smear is normal, then you don’t 
have HPV
21 14
Changes in the Pap smear may indicate 
that you have HPV
43 28.7
A negative test for HPV means that you 
don’t have HPV
15 10
Most people with HPV have no visible 
signs or symptoms
58 38.7
I can transmit HPV, even if I don’t have the 
symptoms
59 39.3
Having one type of HPV means that you 
can’t acquire new types
50 33.3
Awareness of
HPV 34 22.7
Cancer of the cervix 135 90
The Pap smear 105 70
Source of information
Indicated at least one source 139 92.7
Media 81 58.3
Family and friends 23 16.5
Healthcare providers 35 25.2
HPV: human papillomavirus, Pap: Papanicolaou
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both cancer and warts (93.3%). There was low interest 
(42.7%) in the vaccine if it could only prevent warts.
More clients (70%) preferred to be vaccinated with a once-off 
dose, rather than two doses over a three-month period (28%). 
Similarly, most participants (78%) would opt for a vaccine if it 
was administered free of charge rather than having to assume 
the cost of R500 (42.7%). 
A doctor’s recommendation of the vaccine would result 
in higher potential vaccine uptake (84%), although many 
participants indicated that a recommendation from a spouse, 
family member or friend would also motivate them to be 
vaccinated (58.7%).
Table IV shows that the bivariate analysis found that being 
aware of the existence of a Pap smear, and having more 
knowledge about HPV, were associated with a fourfold [odds 
ratio (OR) of 3.54, 95% confidence interval (CI): 1.51-8.27)], 
and a threefold (OR of 2.94, 95% CI: 1.23-7.02) increase in 
the odds of being willing to be vaccinated, respectively. Those 
who believed HPV and its consequences to be severe were 
observed to be five times (OR of 5.42, 95% CI: 2.23-13.2) 
more willing to be vaccinated. Individuals who believed that 
the vaccine was effective were 10 times (OR of 10.09, 95% 
CI: 3.84-16.5) more willing to be vaccinated, compared to 
those who did not believe that the vaccine was effective. 
Discussion
In this study, 22.7% of the participants were aware of HPV. 
This compares fairly well with findings from other studies. A 
systematic review of 60 studies17 on awareness of HPV among 
females of diverse backgrounds reported a range of between 
13% and 93%. In contrast to the low awareness of HPV in 
respondents in this study, most (90%) were aware of cancer 
of the cervix. This could be because HPV is a microbiological 
term, and could be difficult for people without medical training 
people to recall, compared to the term “cancer of the cervix”, 
which the general population would tend to recall more easily. 
The study showed that 70% of the respondents had heard of 
the Pap smear. This is less than the 95% reported for females 
staying in an urban district in Cape Town.8 The difference 
could have arisen because the Cape Town study focused on 
women attending gynecological clinics and they could have 
been more aware of Pap smears because of their contact with 
associated health workers. In this study, it was worrying to 
note that more participants (58%) cited media as a primary 
source of information, rather than healthcare workers (25%). 
Similar findings were also reported [81% (media) versus 2% 
(healthcare workers)] in a study by Moodley et al.8 
However, it was encouraging that 67.3% of the students 
knew of an association between HPV and cancer of the cervix. 
This finding was almost the same (68%) as the one that was 
reported in a study on female university students at Walter 
Sisulu University (formerly the University of Transkei).20
 
This study highlighted confusion between HPV and other 
sexually transmitted infections. For instance, only 9.3% of 
students knew that HPV did not cause herpes. A similar finding 
was also observed in a study21 on female university students, 
wherein 80% thought that there was a link between HPV and 
herpes genitalis. 
Less than a third of respondents were aware of a vaccine to 
Table III: Health beliefs and intention with regard to human papillomavirus 
vaccine uptake
Health beliefs and intention with regard 
to human papillomavirus vaccine 
uptake
Frequency Percentage
Health beliefs
Believe they are at risk of HPV infection 62 41.3
Believe that HPV infection is severe 117 78.8
Believe that the HPV vaccine is effective 125 83.3
Want to be educated more on HPV 147 98
Would opt to be vaccinated if
It was available to them 122 81.3
It prevented warts only 64 42.7
It prevented cancer only 107 71.3
It prevented both 140 93.3
It was one dose, given once off 106 70.7
It was two doses, given three months 
apart
42 28
The vaccine was free of charge 117 78
The vaccine cost R500 64 42.7
It was recommended by a doctor 126 84
It was recommended by a spouse, family 
member or friend
88 58.7
HPV: human papillomavirus
Table IV: Predictors of the uptake of the human papillomavirus vaccine
Predictors Odds ratio 95% confidence 
interval
Sexual behaviour
Being in a relationship 2.20 0.94-5.16
Being sexually active 0.64 0.24-1.72
Having > 1 partner in a six-month 
period
0.68 0.29-1.63
Used a condom during the last 
sexual encounter
1.04 0.41-2.61
Awareness and knowledge of HPV
Awareness of cancer of the cervix 2.43 0.76-7.79
Awareness of HPV 1.96 0.63-6.09
Awareness of the Pap smear 3.54 1.51-8.27
Higher knowledge of HPV 2.94 1.23-7.02
Health beliefs
Believed themselves to be at risk of 
HPV infection
1.99 0.81-5.16
The HPV infection can be severe 5.42 2.23-13.2
The HPV vaccine is effective 10.09 3.84-16.5
Pap: Papanicolaou
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prevent HPV and cervical cancer, and even less (22%) knew 
that the vaccine is available in the country. Eighty per cent 
of respondents would opt to be vaccinated if it was available 
to them, which confirms a high level of acceptability which 
has also been documented in the literature. In urban Turkey, 
acceptability of the HPV vaccine was even higher (96%) in a 
nonrepresentative sample of women attending a gynecological 
clinic.22 Locally, a qualitative study in the Western Cape 
province6 on members of the community revealed that the 
need for a vaccine to prevent cancer resonated with the 
respondents, despite overall poor knowledge of cancer of the 
cervix and its causal relationship with HPV.
A great proportion of our study participants wanted a vaccine 
that would prevent both genital warts and cervical cancer. 
This finding confirmed what was reported by Hoover et al, i.e. 
that 97% of respondents would opt for a vaccine that could 
prevent both diseases. 
This study also revealed that more clients (70%) would prefer 
to be vaccinated with a once-off dose, rather than two doses 
over a three-month period (28%). This may have implications 
with regard to the acceptability of the current vaccine which 
is to be administered via three doses, three months apart, 
with each dose costing R450. Therefore, the total cost of the 
vaccination would be R1 350.23 Moreover, the observation 
that a greater percentage of study participants (78%) would 
prefer a vaccine that was administered free of charge rather 
than one costing R500 (42.7%). This suggests that efforts 
should be invested in finding ways to make the vaccine more 
affordable, and hence accessible, to a greater proportion of 
the populace. 
It was found that a doctor’s recommendation for the vaccine 
would result in a potential 84% vaccine uptake, while a 
recommendation from a spouse, friend or family member 
would lead to an approximate 60% uptake. Such findings 
have been confirmed in studies that were carried out 
elsewhere.24 A physician’s endorsement of a vaccine has been 
identified as an important catalyst for vaccine acceptance. A 
number of studies25-27 have reported that higher acceptability 
of the vaccine was found in subjects who thought that their 
doctors would recommend it. This finding lends support to 
the notion that of various possible modes of action, physician 
recommendation is likely to be key to the success of HPV 
vaccination programmes. This is because physicians may 
be uniquely persuasive in addressing perceived barriers, 
for example, by initiating conversations with patients about 
their concerns, clarifying any misunderstandings and 
recommending the vaccine.
Health belief model constructs as predictors of vaccine 
uptake
HBM constructs have been reported to be predictors of 
potential vaccine uptake.14,12 A number of studies25,28,29 have 
documented that a higher perceived risk of HPV infection 
was associated with higher vaccine acceptability. However, in 
this study, it was found that a higher perceived risk of HPV 
infection was not statistically significantly associated with 
higher vaccine acceptability. 
The study also found that perceived severity was a significant 
predictor of willingness to be vaccinated. This finding is in 
contradiction which the documented literature,25-27 which 
states that perceived severity did not relate to vaccine 
acceptability. This difference could have arisen because 
these studies were carried out in a Western setting, whose 
population’s beliefs could potentially differ from those of the 
predominantly African group in our study.
Perceived vaccine effectiveness was associated with greater 
willingness to be vaccinated in our study. This confirms the 
findings of previous studies.26,30 It was interesting to note that 
our study confirmed the literature24 reports that advocated 
vaccine effectiveness as the most important attribute of an 
acceptable vaccine.
Limitations of the study
Because of the study design, students with a lower frequency 
of accessing their e-mails were likely to be under-represented. 
Thus, the study may be subject to selection bias. Voluntary 
participation may also have resulted in students with an 
interest in the topic self-selecting for the study. However, 
since general knowledge of HPV was low in the respondents, 
it is unlikely that this was the case.
Conclusion
Considerable work needs to be carried out on educating the 
general population about HPV, cancer of the cervix and the 
HPV vaccine in view of the poor knowledge demonstrated 
by university students. It is perhaps assumed that university 
students should have better knowledge of these subjects than 
ordinary women in the community because of their potential 
to attain a higher education and social status. Healthcare 
institutions and workers need to focus on providing this 
information to women. 
There is an urgent need to review the cost of the vaccine, or/
and to make it available in the public health sector so that 
it will be accessible to a greater number of clients. Vaccine 
marketing strategies could educate women on HPV, emphasise 
their susceptibility and the severity of the consequences, and 
convince them about the vaccine’s effectiveness in preventing 
HPV and cervical cancer.
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